
|Videos|July 23, 2014
Predicting Outcomes in Breast Cancer
Author(s)Charles M. Perou, PhD
Charles M. Perou, PhD, professor of genetics, pathology & laboratory medicine, UNC Lineberger Comprehensive Cancer Center, discusses the future of predicting outcomes in breast cancer.
Advertisement
Clinical Pearls
Charles M. Perou, PhD, professor of genetics, pathology & laboratory medicine, UNC Lineberger Comprehensive Cancer Center, discusses the future of predicting outcomes in breast cancer.
- The utility of genomic tests for prognosis is well established and growing in use in breast cancer. Prediction is the next stage.
- Results from the CALGB 40601 study demonstrate that tumor subtype and microenvironment is potentially predictive of pCR rate.
- The best way to measure microenvironment remains to be seen.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5








































